FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Chalcones are potential inhibitors of HIV-1 protease

Halkoni potencijalni inhibitori HIV‐1 proteaze

Thumbnail
2022
Chalcones_are_potential_pub_2022.pdf (234.0Kb)
Authors
Turković, Nemanja
Tasić, Milica
Kotur-Stevuljević, Jelena
Vujić, Zorica
Ivković, Branka
Ivković, Aleksandar
Book part (Published version)
Metadata
Show full item record
Abstract
The discovery of HIV and the study of molecular mechanisms crucial for the virus replication cycle have led to the identification of important protein structures - potential targets of drug action in AIDS therapy. One of the most significant discoveries is HIV-1 protease (PR), an enzyme that plays a key role in the HIV replication cycle (1). This study aimed to test and demonstrate the interactions of newly synthesized chalcones (1,3-diaryl-2- propen-1-one) as well as three commercial drugs (lopinavir, ritonavir and darunavir) in the active site of HIV-1 protease using in sillico methods. and that the results obtained correlate with the results of in vitro tests on the enzyme itself. The twenty structurally similar chalcone derivatives were synthesized and their physico-chemical characterization was performed. Docking calculations were performed using the Autodock Wine program in the 3D structure of the enzime catalytic site (pdb code: 6B36). The inhibition of enzyme activity... was monitored by fluorimetric method (2). The obtained results revealed that all compounds showed anti-HIV-1 protease activity. Compound C1 showed the highest inhibitory activity with an IC 50 values of 0.001 μM which is comparable with commercial product Darunavir. The results obtained indicate that the synthesized compounds can be classified as potential anti-HIV-1 protease inhibitors. Further research is focused on testing the ADMET properties of the synthesized compounds as well as the synthesis of their analogues for which in silico tests have shown satisfactory results.

Otkrić e HIV-a i istraživanje molekularnih mehanizama ključnih za ciklus replikacije virusa dovelo je do identifikacije važnih proteinskih struktura - potencijalnih ciljnih mesta dejstva lekova u terapiji AIDS-a. Jedno od najznačajnijih otkrića je HIV-1 proteaza (PR), enzim koji ima ključnu ulogu u ciklusu replikacije HIV-a (1). Ova studija imala je za cilj da primenom in sillico metoda ispita i prikaže interakcije novosintetisanih halkona (1,3-diaril-2- propen-1-ona) kao i tri komercijalna leka (lopinavira, ritonavira i darunavira) u aktivnom mestu HIV-1 proteaze i da dobijene rezultate koreliše sa rezultatima in vitro testova na samom enzimu. Sintetisano je dvadeset strukturno sličnih derivata halkona i izvršena njihova fizičko-hemijska karakterizacija. Docking studije izvedene su u programu Autodock Vine u 3D strukturi enzimskog katalitičkog mesta (pdb kod: 6B36). Inhibicija enzimske aktivnosti određena je primenom fluorimetrijske metode (2). Dobijeni rezultati ukazuju da... svih 20 jedinjenja ispoljava anti-HIV-1 proteaznu aktivnost. Jedinjenje HNT1 je pokazalo najveć u inhibitornu aktivnost sa vrednostima IC50 od 0,001 μM što je uporedivo sa komercijalnim proizvodom darunavirom. Dobijeni rezultati ukazuju da se sitetisana jedinjenja mogu klasifikovati kao potencijalni anti-HIV-1 proteazni inhibitori. Dalje istraživanje je usmereno na ispitivanju ADMET osobina sintetisanih jedinjenja kao i sintezi njihovih analoga za koje su in silico ispitivanja pokazala zadovoljavajuće rezultate.

Source:
Arhiv za farmaciju, 2022, 72, 4 suplement, S1865-S187
Publisher:
  • Savez farmaceutskih udruženja Srbije (SFUS)
Note:
  • VIII Kongres farmaceuta Srbije sa međunarodnim učešćem, 12-15.10.2022. Beograd

ISSN: 0004-1963

[ Google Scholar ]
Handle
https://hdl.handle.net/21.15107/rcub_farfar_4491
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/4491
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - CHAP
AU  - Turković, Nemanja
AU  - Tasić, Milica
AU  - Kotur-Stevuljević, Jelena
AU  - Vujić, Zorica
AU  - Ivković, Branka
AU  - Ivković, Aleksandar
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4491
AB  - The discovery of HIV and the study of molecular mechanisms crucial for the virus
replication cycle have led to the identification of important protein structures - potential
targets of drug action in AIDS therapy. One of the most significant discoveries is HIV-1
protease (PR), an enzyme that plays a key role in the HIV replication cycle (1). This study
aimed to test and demonstrate the interactions of newly synthesized chalcones (1,3-diaryl-2-
propen-1-one) as well as three commercial drugs (lopinavir, ritonavir and darunavir) in the
active site of HIV-1 protease using in sillico methods. and that the results obtained correlate
with the results of in vitro tests on the enzyme itself. The twenty structurally similar
chalcone derivatives were synthesized and their physico-chemical characterization was
performed. Docking calculations were performed using the Autodock Wine program in the
3D structure of the enzime catalytic site (pdb code: 6B36). The inhibition of enzyme activity
was monitored by fluorimetric method (2). The obtained results revealed that all compounds
showed anti-HIV-1 protease activity. Compound C1 showed the highest inhibitory activity
with an IC 50 values of 0.001 μM which is comparable with commercial product Darunavir.
The results obtained indicate that the synthesized compounds can be classified as potential
anti-HIV-1 protease inhibitors. Further research is focused on testing the ADMET properties
of the synthesized compounds as well as the synthesis of their analogues for which in silico
tests have shown satisfactory results.
AB  - Otkrić e HIV-a i istraživanje molekularnih mehanizama ključnih za ciklus replikacije
virusa dovelo je do identifikacije važnih proteinskih struktura - potencijalnih ciljnih mesta
dejstva lekova u terapiji AIDS-a. Jedno od najznačajnijih otkrića je HIV-1 proteaza (PR),
enzim koji ima ključnu ulogu u ciklusu replikacije HIV-a (1). Ova studija imala je za cilj da
primenom in sillico metoda ispita i prikaže interakcije novosintetisanih halkona (1,3-diaril-2-
propen-1-ona) kao i tri komercijalna leka (lopinavira, ritonavira i darunavira) u aktivnom
mestu HIV-1 proteaze i da dobijene rezultate koreliše sa rezultatima in vitro testova na
samom enzimu. Sintetisano je dvadeset strukturno sličnih derivata halkona i izvršena
njihova fizičko-hemijska karakterizacija. Docking studije izvedene su u programu Autodock
Vine u 3D strukturi enzimskog katalitičkog mesta (pdb kod: 6B36). Inhibicija enzimske
aktivnosti određena je primenom fluorimetrijske metode (2). Dobijeni rezultati ukazuju da
svih 20 jedinjenja ispoljava anti-HIV-1 proteaznu aktivnost. Jedinjenje HNT1 je pokazalo
najveć u inhibitornu aktivnost sa vrednostima IC50 od 0,001 μM što je uporedivo sa
komercijalnim proizvodom darunavirom. Dobijeni rezultati ukazuju da se sitetisana
jedinjenja mogu klasifikovati kao potencijalni anti-HIV-1 proteazni inhibitori. Dalje
istraživanje je usmereno na ispitivanju ADMET osobina sintetisanih jedinjenja kao i sintezi
njihovih analoga za koje su in silico ispitivanja pokazala zadovoljavajuće rezultate.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
T2  - Arhiv za farmaciju
T1  - Chalcones are potential inhibitors of HIV-1 protease
T1  - Halkoni potencijalni inhibitori HIV‐1 proteaze
VL  - 72
IS  - 4 suplement
SP  - S1865
EP  - S187
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4491
ER  - 
@inbook{
author = "Turković, Nemanja and Tasić, Milica and Kotur-Stevuljević, Jelena and Vujić, Zorica and Ivković, Branka and Ivković, Aleksandar",
year = "2022",
abstract = "The discovery of HIV and the study of molecular mechanisms crucial for the virus
replication cycle have led to the identification of important protein structures - potential
targets of drug action in AIDS therapy. One of the most significant discoveries is HIV-1
protease (PR), an enzyme that plays a key role in the HIV replication cycle (1). This study
aimed to test and demonstrate the interactions of newly synthesized chalcones (1,3-diaryl-2-
propen-1-one) as well as three commercial drugs (lopinavir, ritonavir and darunavir) in the
active site of HIV-1 protease using in sillico methods. and that the results obtained correlate
with the results of in vitro tests on the enzyme itself. The twenty structurally similar
chalcone derivatives were synthesized and their physico-chemical characterization was
performed. Docking calculations were performed using the Autodock Wine program in the
3D structure of the enzime catalytic site (pdb code: 6B36). The inhibition of enzyme activity
was monitored by fluorimetric method (2). The obtained results revealed that all compounds
showed anti-HIV-1 protease activity. Compound C1 showed the highest inhibitory activity
with an IC 50 values of 0.001 μM which is comparable with commercial product Darunavir.
The results obtained indicate that the synthesized compounds can be classified as potential
anti-HIV-1 protease inhibitors. Further research is focused on testing the ADMET properties
of the synthesized compounds as well as the synthesis of their analogues for which in silico
tests have shown satisfactory results., Otkrić e HIV-a i istraživanje molekularnih mehanizama ključnih za ciklus replikacije
virusa dovelo je do identifikacije važnih proteinskih struktura - potencijalnih ciljnih mesta
dejstva lekova u terapiji AIDS-a. Jedno od najznačajnijih otkrića je HIV-1 proteaza (PR),
enzim koji ima ključnu ulogu u ciklusu replikacije HIV-a (1). Ova studija imala je za cilj da
primenom in sillico metoda ispita i prikaže interakcije novosintetisanih halkona (1,3-diaril-2-
propen-1-ona) kao i tri komercijalna leka (lopinavira, ritonavira i darunavira) u aktivnom
mestu HIV-1 proteaze i da dobijene rezultate koreliše sa rezultatima in vitro testova na
samom enzimu. Sintetisano je dvadeset strukturno sličnih derivata halkona i izvršena
njihova fizičko-hemijska karakterizacija. Docking studije izvedene su u programu Autodock
Vine u 3D strukturi enzimskog katalitičkog mesta (pdb kod: 6B36). Inhibicija enzimske
aktivnosti određena je primenom fluorimetrijske metode (2). Dobijeni rezultati ukazuju da
svih 20 jedinjenja ispoljava anti-HIV-1 proteaznu aktivnost. Jedinjenje HNT1 je pokazalo
najveć u inhibitornu aktivnost sa vrednostima IC50 od 0,001 μM što je uporedivo sa
komercijalnim proizvodom darunavirom. Dobijeni rezultati ukazuju da se sitetisana
jedinjenja mogu klasifikovati kao potencijalni anti-HIV-1 proteazni inhibitori. Dalje
istraživanje je usmereno na ispitivanju ADMET osobina sintetisanih jedinjenja kao i sintezi
njihovih analoga za koje su in silico ispitivanja pokazala zadovoljavajuće rezultate.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
booktitle = "Chalcones are potential inhibitors of HIV-1 protease, Halkoni potencijalni inhibitori HIV‐1 proteaze",
volume = "72",
number = "4 suplement",
pages = "S1865-S187",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4491"
}
Turković, N., Tasić, M., Kotur-Stevuljević, J., Vujić, Z., Ivković, B.,& Ivković, A.. (2022). Chalcones are potential inhibitors of HIV-1 protease. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S1865-S187.
https://hdl.handle.net/21.15107/rcub_farfar_4491
Turković N, Tasić M, Kotur-Stevuljević J, Vujić Z, Ivković B, Ivković A. Chalcones are potential inhibitors of HIV-1 protease. in Arhiv za farmaciju. 2022;72(4 suplement):S1865-S187.
https://hdl.handle.net/21.15107/rcub_farfar_4491 .
Turković, Nemanja, Tasić, Milica, Kotur-Stevuljević, Jelena, Vujić, Zorica, Ivković, Branka, Ivković, Aleksandar, "Chalcones are potential inhibitors of HIV-1 protease" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S1865-S187,
https://hdl.handle.net/21.15107/rcub_farfar_4491 .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB